Comparative Pharmacology
Head-to-head clinical analysis: CHLOROMYCETIN versus NEOBIOTIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLOROMYCETIN versus NEOBIOTIC.
CHLOROMYCETIN vs NEOBIOTIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation.
NEOBIOTIC is a combination antibiotic product containing neomycin (aminoglycoside) and bacitracin (polypeptide antibiotic). Neomycin binds to the 30S ribosomal subunit of bacteria, causing misreading of mRNA and inhibiting protein synthesis. Bacitracin inhibits bacterial cell wall synthesis by interfering with dephosphorylation of the lipid carrier that transports peptidoglycan subunits.
50-100 mg/kg/day IV divided every 6 hours; maximum 4 g/day. Topical: apply to affected area 2-4 times daily.
1 g intravenously every 12 hours.
None Documented
None Documented
1.5-4 hours in adults; prolonged to 3-7 hours in neonates and 4-12 hours in hepatic impairment; clinical context: dose adjustment required in liver disease.
3.5–4.5 hours (terminal) in adults with normal renal function; prolonged to 12–18 hours in severe renal impairment (CrCl <30 mL/min).
Renal: 5-10% unchanged; hepatic glucuronidation (90%) followed by renal elimination of metabolites; small biliary excretion (<5%) and fecal elimination.
Renal: 30–40% unchanged; fecal: 50–60% via biliary elimination; minimal hepatic metabolism.
Category C
Category C
Antibiotic
Antibiotic